ChoA Pharmaceutical Co (034940) Fair Value & Analysis
Healthcare · KR · Market cap 22.0B KRW
Fair value as of: Jul 22, 2026
From 3 valuation models · updated today
Share price −4.1% over the past month.
Price vs Fair Value (12 months)
12‑month range 505.00 KRW – 1,269 KRW · fair‑value band 44.44 KRW – 88.47 KRW · the 632.00 KRW price screens above the 65.18 KRW fair value. As of Jul 22, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
ChoA Pharmaceutical Co (034940) currently trades at 632.00 KRW, while our model-based Fair Value estimate is 65.18 KRW, implying the stock looks roughly 89.7% overvalued today. We read business quality at 35/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, ChoA Pharmaceutical Co generated revenue of 59.6B KRW at a net margin of -7.9%. Revenue grew 2.1% year over year. It earns a return on equity of -22.1%. Net debt stands at 22.7B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 44.44 KRW (bear case) to 88.47 KRW (bull case); at 632.00 KRW, the current price sits above that range. The share trades about 55% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -90%, 034940 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 22, 2026. TTM = trailing twelve months.
About the company
ChoA Pharmaceutical Co., Ltd. operates as a pharmaceutical company in South Korea. The company produces approximately 200 medicines and health foods, including 30 internal ampoule products, such as Hepos, Fematin, Vasoclean, Mabis, etc. Its products include drugs for digestive, circulatory, and respiratory systems; vitamins, minerals, and nutrients; anti inflammation and analgesics; peripheral nervous system; gynecologic diseases; antibiotics, antigens, and anthelmintic; and antitumor, as well as other metabolite medicines. The company offers its products in the form of tablets, capsules, granules, syrups, solutions, drinkable ampoules, and sachets. It also provides medicine supply and pharmacy management services. The company exports its products to approximately 20 countries worldwide. The company was founded in 1964 and is headquartered in Seoul, South Korea.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
ChoA Pharmaceutical Co reported revenue of 59.3B KRW in FY2025 versus 57.6B KRW in FY2021, a compound +0.8%/yr. Reported net income was −6.8B KRW in FY2025.
Is 034940 fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.01 | ¥26.59 | -43% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹6,623 | ₹1,461 | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,421 | ₹1,504 | -66% |
| PharmaEssentia Corporation 6446 | 937.00 TWD | 322.35 TWD | -66% |
| Cipla Limited CIPLA | ₹1,416 | ₹1,466 | +4% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Lupin Limited LUPIN | ₹2,340 | ₹2,477 | +6% |
| Mankind Pharma Limited MANKIND | ₹2,543 | ₹983.32 | -61% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,278 | ₹595.34 | -53% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is ChoA Pharmaceutical Co (034940) undervalued?
What is the fair value of 034940?
What is the quality score of 034940?
What is the revenue of ChoA Pharmaceutical Co (034940)?
What is the net profit margin of 034940?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full ChoA Pharmaceutical Co analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.